Mohamed Mahi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mohamed Mahi has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Adil Debbagh
Department of Medical Oncology, University Military Hospital, Rabat, 10000, Morocco
2 shared publications - Amal Rami
Professor of Radiology, Mohammed VI Center for Research and Innovation, Cheikh Khalifa International University Hospital, Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco
2 shared publications - Hassan Errihani
National Institute of Oncology
2 shared publications - Khaoula Slimani
Department of Medical Oncology, University Military Hospital, Rabat, 10000, Morocco
2 shared publications - Mohammed Ichou
Department of Medical Oncology, University Military Hospital, Rabat, 10000, Morocco
2 shared publications - Yassir Sbitti
Department of Medical Oncology, Mohammed V Military Hospital, Rabat, Morocco
2 shared publications
Latest Publications
- Open Access
- 21 June 2023
- Published by Elsevier in Urology Case Reports
- Vol. 50, 102475
Rare images of renal mass and lithiasis in native kidney after renal transplantation in a patient with hematuria: Casual or correlated?
- 21 June 2023
- Published by Elsevier in Urology Case Reports
- Vol. 50, 102475
Open AccessRare images of renal mass and lithiasis in native kidney after renal transplantation in a patient with hematuria: Casual or correlated?
- Open Access
- 1 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32109
Fortuitous Discovery of Nutcracker Syndrome During Acute Appendicitis: A Case Report
Nutcracker syndrome (NCS) belongs to a group of rare vascular disorders. It refers to compression of the left renal vein (LRV) generally between the abdominal aorta (AA) and the superior mesenteric artery (SMA). It is one of the most unknown causes of chronic abdominal pain. Herein, we present the case of a young patient who came to the emergency department for acute abdominal pain. Patient's history revealed an uncharacterized chronic epigastric pain evolving for 13 years. The imaging showed acute appendicitis and NCS; the latter finding was the principal explanation for the patient’s chronic pain. We hope that the concise and synthetized structure of this case report will help physicians acquire the necessary reflexes to notice and diagnose this already underdiagnosed syndrome.
- 1 December 2022
- Published by Springer Nature in Cureus
- Vol. 14 (12) , e32109
Open AccessFortuitous Discovery of Nutcracker Syndrome During Acute Appendicitis: A Case Report
Nutcracker syndrome (NCS) belongs to a group of rare vascular disorders. It refers to compression of the left renal vein (LRV) generally between the abdominal aorta (AA) and the superior mesenteric artery (SMA). It is one of the most unknown causes of chronic abdominal pain. Herein, we present the case of a young patient who came to the emergency department for acute abdominal pain. Patient's history revealed an uncharacterized chronic epigastric pain evolving for 13 years. The imaging showed acute appendicitis and NCS; the latter finding was the principal explanation for the patient’s chronic pain. We hope that the concise and synthetized structure of this case report will help physicians acquire the necessary reflexes to notice and diagnose this already underdiagnosed syndrome.
- Open Access
- 19 May 2022
- Published by Springer Nature in Cureus
- Vol. 14 (5) , e25149
Cataclysmic Gastrointestinal Hemorrhage: Dreaded Complication of Metastatic Breast Cancer
Upper gastrointestinal bleeding (UGIB) from variceal rupture is a serious condition that can be life-threatening in some cases. Usually, the main cause is portal hypertension in cirrhosis, but other etiologies like liver metastases can be also involved. We present the case of a 64-year-old woman, with a history of metastatic breast cancer, who was admitted for a massive UGIB due to ruptured esophageal varices related to portal hypertension.
- 19 May 2022
- Published by Springer Nature in Cureus
- Vol. 14 (5) , e25149
Open AccessCataclysmic Gastrointestinal Hemorrhage: Dreaded Complication of Metastatic Breast Cancer
Upper gastrointestinal bleeding (UGIB) from variceal rupture is a serious condition that can be life-threatening in some cases. Usually, the main cause is portal hypertension in cirrhosis, but other etiologies like liver metastases can be also involved. We present the case of a 64-year-old woman, with a history of metastatic breast cancer, who was admitted for a massive UGIB due to ruptured esophageal varices related to portal hypertension.
- Open Access
- 1 January 2021
- Published by Oxford University Press (OUP) in BJR|case reports
- Vol. 7 (1)
Ansa pancreatica: a rare cause of acute recurrent episode in chronic pancreatitis
Ansa pancreatica is a rare anatomic variation of pancreatic ducts. It’s a predisposing factor of recurrent pancreatitis. In this case report, we describe a case of a 24-year-old male suffering from an ansa pancreatica with a non-patent major papilla, diagnosed on magnetic resonance cholangiopancreatography (MRCP).The Ansa pancreatica was revealed by an episode ofacute pancreatitis attacks in chronic pancreatitis.Endoscopic retrograde cholangiopancreatography (ERCP) confirmed importantabrupt dilation in the main pancreatic duct with an ansa loop in the PD (pancreatic duct) in the head of the pancreas, and a sphincterotomy of the minor papilla was performed.The procedure was difficult and the placement of a long-term pancreatic stent during the ERCP was impossible, thus a surgical pancreatico-jejunostomy was proposed as a treatment of an ansa pancreatica with a non-patent major papilla.
- 1 January 2021
- Published by Oxford University Press (OUP) in BJR|case reports
- Vol. 7 (1)
Open AccessAnsa pancreatica: a rare cause of acute recurrent episode in chronic pancreatitis
Ansa pancreatica is a rare anatomic variation of pancreatic ducts. It’s a predisposing factor of recurrent pancreatitis. In this case report, we describe a case of a 24-year-old male suffering from an ansa pancreatica with a non-patent major papilla, diagnosed on magnetic resonance cholangiopancreatography (MRCP).The Ansa pancreatica was revealed by an episode ofacute pancreatitis attacks in chronic pancreatitis.Endoscopic retrograde cholangiopancreatography (ERCP) confirmed importantabrupt dilation in the main pancreatic duct with an ansa loop in the PD (pancreatic duct) in the head of the pancreas, and a sphincterotomy of the minor papilla was performed.The procedure was difficult and the placement of a long-term pancreatic stent during the ERCP was impossible, thus a surgical pancreatico-jejunostomy was proposed as a treatment of an ansa pancreatica with a non-patent major papilla.
- Open Access
- 20 March 2018
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 12 (1) , 80
When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report
Long-term survival with durable response remains possible in the area of targeted therapies. Discontinuation of sunitinib could improve quality of life and reduce treatment costs in metastatic renal cell carcinoma with long-term disease stabilization. We discuss a case of successful interruption of antiangiogenic therapy in a patient with persisting evidence of metastases. The discontinuation of antiangiogenic therapy seems to be an option, even in indolent oligo-metastatic renal cell carcinoma with long disease stabilization before sunitinib. This observation contributes important data to the ongoing discussion on the discontinuation of treatment with kinase inhibitors in selected patients with metastatic renal cell carcinoma. We report a case of an 80-year-old Moroccan man treated for renal clear cell carcinoma with multiple pancreatic metastases. He was not on any other medications. He underwent active surveillance with deferred sunitinib at disease progression. He showed significant disease control on sunitinib therapy demonstrating partial response with stable disease after a total of 28 months of therapy. He experienced toxicities which were manageable with supportive care and dose adjustments. Our patient asked for a break of the sunitinib administration, and the treatment was stopped. The disease remained stable after 13 months’ discontinuation of sunitinib therapy. The patient was in excellent overall health. All available agents for metastatic renal cell carcinoma have side effects, which may become serious in a minority of patients. Clinicians and patients must therefore carefully balance the goals of maximal efficacy with minimal toxicity. Sunitinib can be discontinued without negatively impacting outcomes in indolent disease. Further research is needed to characterize the molecular determinants of response and resistance to targeted therapy.
- 20 March 2018
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 12 (1) , 80
Open AccessWhen tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report
Long-term survival with durable response remains possible in the area of targeted therapies. Discontinuation of sunitinib could improve quality of life and reduce treatment costs in metastatic renal cell carcinoma with long-term disease stabilization. We discuss a case of successful interruption of antiangiogenic therapy in a patient with persisting evidence of metastases. The discontinuation of antiangiogenic therapy seems to be an option, even in indolent oligo-metastatic renal cell carcinoma with long disease stabilization before sunitinib. This observation contributes important data to the ongoing discussion on the discontinuation of treatment with kinase inhibitors in selected patients with metastatic renal cell carcinoma. We report a case of an 80-year-old Moroccan man treated for renal clear cell carcinoma with multiple pancreatic metastases. He was not on any other medications. He underwent active surveillance with deferred sunitinib at disease progression. He showed significant disease control on sunitinib therapy demonstrating partial response with stable disease after a total of 28 months of therapy. He experienced toxicities which were manageable with supportive care and dose adjustments. Our patient asked for a break of the sunitinib administration, and the treatment was stopped. The disease remained stable after 13 months’ discontinuation of sunitinib therapy. The patient was in excellent overall health. All available agents for metastatic renal cell carcinoma have side effects, which may become serious in a minority of patients. Clinicians and patients must therefore carefully balance the goals of maximal efficacy with minimal toxicity. Sunitinib can be discontinued without negatively impacting outcomes in indolent disease. Further research is needed to characterize the molecular determinants of response and resistance to targeted therapy.
- Open Access
- 23 August 2016
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 14 (1) , 222
Metachronous pancreatic metastases from renal cell carcinoma: is there a place of Active-Surveillance before deferred deliberately Molecular Target Agent?
Metastatic renal cell cancer is a heterogeneous disease due to its diverse morphological features, the prognostic categories based on clinical criteria. Sometimes indolent course without any significant symptoms can be differentiated before the introduction of novel targeted agents. This observation led to interest in a strategy of deferring systemic therapy in the era of effective systemic therapies. We report of a 78-year-old Moroccan man with pancreatic metastasis from renal cell carcinoma which occurred 14 years from right nephrectomy. Indolent disease based on body computed tomography imaging with 4 years follow-up was recognized. Active surveillance with deferred antiangiogenic multikinase inhibitor at disease progression was proposed. Nowadays, the patient is under oncological follow-up, he is in a good state of health, and he is disease-free for 48 months from the diagnosis of the tumor and for 20 months from the start of the treatment with Sunitinib Active surveillance before target therapy may be a suitable approach to ensure long progression-free survival with minimal side-effects and better quality of life in asymptomatic, low-volume, metastatic disease. Further prospective studies with biomarker validation are required to define the patients most likely to benefit from this approach.
- 23 August 2016
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 14 (1) , 222
Open AccessMetachronous pancreatic metastases from renal cell carcinoma: is there a place of Active-Surveillance before deferred deliberately Molecular Target Agent?
Metastatic renal cell cancer is a heterogeneous disease due to its diverse morphological features, the prognostic categories based on clinical criteria. Sometimes indolent course without any significant symptoms can be differentiated before the introduction of novel targeted agents. This observation led to interest in a strategy of deferring systemic therapy in the era of effective systemic therapies. We report of a 78-year-old Moroccan man with pancreatic metastasis from renal cell carcinoma which occurred 14 years from right nephrectomy. Indolent disease based on body computed tomography imaging with 4 years follow-up was recognized. Active surveillance with deferred antiangiogenic multikinase inhibitor at disease progression was proposed. Nowadays, the patient is under oncological follow-up, he is in a good state of health, and he is disease-free for 48 months from the diagnosis of the tumor and for 20 months from the start of the treatment with Sunitinib Active surveillance before target therapy may be a suitable approach to ensure long progression-free survival with minimal side-effects and better quality of life in asymptomatic, low-volume, metastatic disease. Further prospective studies with biomarker validation are required to define the patients most likely to benefit from this approach.